News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cytheris SA Announces Publication of IL-7 Oncology Data in The Journal of Experimental Medicine



6/26/2008 9:12:30 AM

PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, non-lymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S. National Cancer Institute (NCI) investigators lead by Claude Sport├Ęs, Crystal Mackall and Ronald Gress, support the potential of the IL-7 investigational product as an immunotherapy for the treatment of patients with impaired immunity due to physiologic (age), iatrogenic (chemotherapy or transplantation) or pathologic (HIV) lymphodepletion.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES